×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Merck compares pneumococcal vaccine to 1983 warhorse
Fierce Biotech
Merck has presented successful clinical results for its investigational pneumococcal vaccine V116, which is up for FDA approval in June of...
6 hours ago
Merck & Co., Inc. (NYSE:MRK) Just Released Its First-Quarter Earnings: Here's What Analysts Think
Yahoo Finance
Merck & Co., Inc. ( NYSE:MRK ) just released its quarterly report and things are looking bullish. The company beat...
2 days ago
Merck KGaA, Huma collab bears fruit with launch of bladder cancer patient support app
Fierce Pharma
Just a few months after announcing their team-up, Merck KGaA and Huma Therapeutics have already checked off the first item on their joint...
3 hours ago
Merck Shines in Q1 2024 Earnings Surge
The Motley Fool
Merck (MRK 0.37%), a global leader in pharmaceuticals, released its first-quarter earnings for 2024 on April 25, revealing a performance...
3 days ago
Merck, Huma alliance bears fruit with UK bladder cancer app
Pharmaphorum
A partnership between Huma Therapeutics and Merck KGaA to develop digital support tools for cancer patients has borne fruit with the launch...
9 hours ago
Merck KGaA earmarks €300M for an advanced research center at its HQ site
Fierce Pharma
Merck KGaA will shell out 300 million euros ($321 million) to build a new research center at the pharma giant's headquarters in Darmstadt,...
5 hours ago
Merck KGaA's Dividend Analysis
Yahoo Finance
Merck KGaA (MKKGY) recently announced a dividend of $0.47 per share, payable on 2024-05-09, with the ex-dividend date set for 2024-04-29.
8 hours ago
Merck late-stage data strengthens profile of pneumonia vaccine candidate
Seeking Alpha
New data from a phase 3 study of Merck's (NYSE:MRK) experimental pneumococcal conjugate vaccine, V116, found that immune responses were...
5 hours ago
Merck beats earnings expectations, raises outlook on strong Keytruda and vaccine sales
CNBC
Merck reported first-quarter revenue and adjusted earnings that topped expectations as it posted strong sales of its blockbuster cancer drug...
4 days ago
Millions of Girls in Africa Will Miss HPV Shots After Merck Production Problem
The New York Times
The company has told countries that it can supply only 18.8 million of the 29.6 million doses it was contracted to deliver this year.
1 week ago